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Background: Enterovirus 71 (EV71) is a major causative agent of hand-foot-and-mouth disease (HFMD), and
infection of EV71 to central nerve system (CNS) may result in a high mortality in children less than 2 years old.
Although there are two highly glycosylated membrane proteins, SCARB2 and PSGL-1, which have been identified as
the cellular and functional receptors of EV71, the role of glycosylation in EV71 infection is still unclear.
Results: We demonstrated that the attachment of EV71 to RD and SK-N-SH cells was diminished after the removal
of cell surface sialic acids by neuraminidase. Sialic acid specific lectins, Maackia amurensis (MAA) and Sambucus
Nigra (SNA), could compete with EV71 and restrained the binding of EV71 significantly. Preincubation of RD cells
with fetuin also reduced the binding of EV71. In addition, we found that SCARB2 was a sialylated glycoprotein and
interaction between SCARB2 and EV71 was retarded after desialylation.
Conclusions: In this study, we demonstrated that cell surface sialic acids assist in the attachment of EV71 to host
cells. Cell surface sialylation should be a key regulator that facilitates the binding and infection of EV71 to RD and
SK-N-SH cells.
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Enterovirus 71 (EV71), an RNA virus of the Picornaviri-
dae family, is first recognized from the patients with
neurological abnormalities in California in 1969 [1]. It is
known to be a causative agent of hand-foot-and-mouth
disease (HFMD), and occasionally its infection would
lead to severe complications including encephalitis,
aseptic meningitis, pulmonary edema or hemorrhage,
and acute flaccid paralysis [2]. Outbreaks of EV71 had
been reported worldwide during the last decade [2–7].
In Taiwan, there was a large epidemic of HFMD in 1998.
More than 120,000 cases were reported and the out-
break resulted in 78 deaths [2]. Two years later, there* Correspondence: affa@mail.ncku.edu.tw
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reproduction in any medium, provided the orwas another outbreak of HFMD with 80,677 reports and
41 deaths (data from CDC, Taiwan). EV71 can induce
the apoptosis of human glioblastoma cells [8], human
microvascular endothelial cells [9], and Jurkat cells [10].
Although it has been demonstrated that the spinal cord
and brain stem were the target of EV71 infections [6,11],
the infection mechanism, tissue tropism, and the neuro-
virulence of EV71 remain unclear.
In 2009, two receptors for EV71 were discovered
[12,13]. Nishimura et al. found that human P-selectin
glycoprotein ligand-1 (PSGL-1) was a functional recep-
tor for EV71 [12]. Yamayoshi et al. reported that scaven-
ger receptor class B2 (SCARB2) was cellular receptor for
EV71 [13]. PSGL-1 is glycosylated with sialyl Lewisx epi-
tope, and SCARB2 is also a highly glycosylated protein.
According to these results, cell surface glycans should
participate in the infection of EV71. Hence, the glycomic
factors which contribute to the epidemics of EV71 infec-
tion have attracted our attention.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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many physiological and pathological communications by
interacting with their corresponding proteins or recep-
tors [14,15]. Among these events, cell surface glycan
receptors which mediate viral binding and infection were
well documented. For instance, Jackson et al. indicated
that the entry of food-and-mouse disease virus (FMDV)
into cell was initiated by the contact with cell surface
heparin sulfate [16]. Sulfated polysaccharides extracted
from sea algae were demonstrated having potential to
prevent the infection of viruses including herpes simplex
virus (HSV), cytomegalovirus (CMV), human immuno-
deficiency virus (HIV) and enterovirus [17–21]. Lactofer-
rin, an 80 kDa iron binding glycoprotein presented in
several mucosal secretions [22,23], was reported to in-
hibit interaction between EV71 VP1 to RD cells [24,25].
In addition, sialic acids were cell surface ligands for many
hemagglutinins (HAs) or viral proteins (VPs) including
influenza, parainfluenza, reovirus type3, adenovirus type
37, human rhinovirus 87, human enterovirus type 70
[26], coxsackievirus A24 [27], and hepatitis A virus [28].
Since the role and function of surface glycans in the
attachment and infection of EV71 is still vague, thisFigure 1 The attachment and infection of EV71 to RD cells are affecte
neuraminidase followed by infection with EV71 MP4. The bound virus was
virus to RD cells treated with different units of neuraminidase was reduced
by flow cytometry (B), and by 20% and 27% measured by real-time PCR (C
treated cells measured by analyzing the copy number of EV71 RNA using r
(two-tailed test). Each of the results was averaged from at least six indepenpaper aims to decipher these issues and figure out the
most important glycomic constituents. Two EV71 sus-
ceptible human cell lines, rhabdomyosarcoma cells (RD
cells) and human neuroblastoma cells (SK-N-SH cells),
are subjected to virus binding assay. Cells were pre-
treated with neuraminidase or α2-3/α2-6 sialic acid
binding lectins (MAA/SNA) for revealing the role of cell
surface sialic acids during EV71 attachment. In addition,
fetuin (a highly sialylated glycoprotein) was subjected to
validate the interaction of sialic acids with EV71. The sig-
nificance of sialylation on SCARB2 was also evaluated.
Results
Role of sialylation in EV71 infection
Since sialic acids participated in the attachment of many
viruses of the Picornaviridae family [28,29], we verified
the effects of sialic acids in EV71 infection. RD cells pre-
treated with different units of neuraminidase were sub-
jected to the binding of EV71 by ELISA, flow-cytometry
and real-time PCR assay. We found that the binding of
EV71 to RD cells decreased dramatically in a dose
dependent manner, which was accompanied with the in-
creasing units of neuraminidase treatment (19-24% ind by neuraminidase treatment. Cells were pretreated with
analyzed by ELISA, flow cytometry and real-time PCR. The binding of
by 20% and 32% measured by ELISA (A), by 27% and 29% measured
). The replication of EV71 dropped by 49% and 66% in neuraminidase
eal-time PCR after 24 hours incubation (D). **: P< 0.01; ***: P< 0.001
dent assays.
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time PCR and 48-66% in real-time PCR assay after 24
hours incubation; Figure 1 A-D). A clear cytopathic ef-
fect was also observed along with the decrease of neur-
aminidase used in EV71-GFP infected RD cells
(Figure 2). It should be noted that the expression of cell
surface SCARB2 was nearly the same after neuraminid-
ase treatment (Figure 3).
Based on these results, we further investigated the si-
alic acid linkage preference of EV71 by lectin competi-
tion assay and carbohydrate solution microarray [30].
MAA preferentially recognized α2-3 linked sialosides
and SNA specifically interacted with α2-6 linked sialo-
sides. As shown in Figure 4 A-F, preincubation of RD
cells with MAA or SNA reduced the interactions of
EV71 to RD cells up to 68% in a dose dependent man-
ner. The retarded cytopathic effect also indicated that
the replication of EV71-GFP in RD-cells was decreased
by lectin treatment (Figure 5). These findings demon-
strated that EV71 may interact with both α2-3 and α2-6
linked sialylated glycoproteins on RD cell surface. Add-
itionally, the same results and inhibition trends wereFigure 2 The infection and replication of EV71 to RD cells are affecte
infection. Cells pretreated with or without neuraminidase (5 mU and 25 m
fluorescence intensity were observed by fluorescence microscope. After 48
neuraminidase pretreated cells.obtained when we applied the same assays on SK-N-SH
cells which were infected with EV71 4643 (X, Y, and Z%
in real-time PCR assays; Figure 6 A-C).
Because it has been reported that lactoferrin, a highly
sialylated glycoprotein, can inhibit the infection of EV71
[24,25], we used another highly sialylated glycoprotein to
confirm these interactions between EV71 with sialic
acid. Fetuin and asialofetuin were subjected to EV71
binding assay. Not surprisingly, pretreated cells with
fetuin reduced the attachment of EV71 to RD cells by
12-14% (statistically significant, Figure 7). These findings
encouraged us to identify the carbohydrate ligands for
EV71 viral particles and VP1 protein (recombinant pro-
tein from E. coli) by glycan solution microarray. But, un-
fortunately, none of the binding signals were observed
(Additional file 1 Supplementary information).
Characterization of SCARB2 sialylation in EV71 infection
Based on these findings, we tried to look deep inside the
relationships of sialylation with viral receptor. By using
lectin affinity chromatography (LAC) which contained
MAA and SNA-agarose beads, we purified sialylatedd by neuraminidase treatment investigated with EV71-GFP
U) were infected with or without EV71-GFP. The cell number, CPE, and
hours, higher fluorescence intensity was found in untreated cells than
Figure 3 The expression of RD cell surface SCARB2 with or
without neuraminidase treatment measured by flow cytometry.
Cell surface SCARB2 was nearly the same after 25 mU of
neuraminidase treatment.
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Desialylation was performed with neuraminidase on
purified glycoproteins to remove sialic acids. The desia-
lylated glycoproteins were subjected to immunoprecipi-
tation assay, in which EV71 viral particles were
immobilized on protein G agarose beads through anti-
EV71 antibody. As shown in Figure 8, the cellular recep-
tor of EV71, SCARB2, was observed in all of the purified
and immunoprecipitated protein fractions. Because of
the neuraminidase treatment, band in lane 3 was slightly
shifted down. In addition, band in lane 4 was slightly
shifted up owing to the non-reducing treatment of EV71
pulled down fractions. To determine whether sialylation
on SCARB2 contribute to its interaction with EV71, the
binding of EV71 to recombinant human SCARB2
(hSCARB2, with or without neuraminidase treatment)
was analyzed by virus overlay protein binding assay
(VOPBA). The result showed that desialylation of
hSCARB2 curtailed the binding ability with EV71
(Figure 9).
Discussion
Glycans that expressed on cell surface are involved in cell-
cell adhesion, leukocyte rolling, cell-extracellular matrix
interaction, and microbes’ infection [31–33]. Carbohy-
drates, especially sialic acids, are also reported as receptors
for gram positive or negative bacteria, viruses, protozoa,
and plant lectins [28]. For example, sialyl Lewisx is a ligand
for the SabA protein of Helicobacter pylori [34]. Choleratoxin of Vibrio chlolerae specifically binds to the GM1
moiety [35]. Human influenza virus recognizes α2-6 sialy-
lated glycans and infects host cells subsequently [36,37].
Glycosaminoglycan, such as hyaluronic acid and chondro-
itin sulfate, are confirmed as antiviral agents in preventing
Coxsackievirus B5 and dengue virus, respectively [38,39].
Further, sialic acid is reported as receptors of many Picor-
naviridae viruses [28,29].
Several methods were established to evaluate the attach-
ment and reproduction efficiency of EV71. ELISA assay
and flow cytometry provided reliable and reproducible
results in quantifying bound EV71 viral particles on cell
surface. The binding and subsequent replication of EV71
was detected by measuring the copy number of viral RNA
by real-time PCR. In addition, the infection and replica-
tion of EV71 could also be confirmed by observing the
fluorescence intensity and cytopathic effects in EV71-GFP
infected cells. RD is an EV71 highly susceptible cell line
which has been applied for viral replication. SK-N-SH cells
established from human neuroblastoma were cell model
for investigating the EV71 caused neuron toxicity. RD and
SK-N-SH cells were infected with EV71 MP4 (mouse
adapted strain) and EV71 4643 (human clinical isolates),
respectively [40].
Since glycosylation was a common and significant fea-
ture for cellular and functional receptors of EV71, we
first investigated the effects of tunicamycin and benzyl-
α-GalNAc (inhibitor for protein N- and O-glycosylation,
respectively) in the binding and infection of EV71 to RD
cells. Both of the inhibitors decreased the binding of
EV71 to RD cells significantly (data not shown). We thus
investigated whether the terminal sialic acids on cell sur-
face was involved in EV71 infection to RD and SK-N-SH
cells. We found that the expression of cell surface
SCARB2 was slightly increased after neuraminidase
treatment, and neuraminidase treatment reduced virus
binding to RD and SK-N-SH cells in a dose-dependent
manner. In addition, the replication of virus was
decreased because the binding of EV71-GFP to RD cells
was reduced after neuraminidase treatment. These
results indicated that sialylation on cell surface should
be involved in the attachment and infection of EV71.
As long as there are two major glycosidic linkages be-
tween sialic acid with galactose, we applied the lectin
competition assay to characterize the binding preference
of EV71 to RD and SK-H-SN cells. Not surprisingly, the
binding of EV71 was restrained by both lectins on RD and
SK-H-SN cells. Both cell surface α2-3- and α2-6-linked
sialosides were participated in the binding of EV71 to host
cells. The replication of virus was also dropped because
the interaction of EV71-GFP to RD cells was blocked by
MAA or SNA. These observations can also be found in
the infection of other Picornaviridae viruses such as
human rhinovirus 87, encephalomyocarditis virus, and
Figure 4 The attachment and infection of EV71 to RD cells are affected by sialic acid specific lectin treatment. Cells were preincubated
with MAA (maackia amurensis) or SNA (sambucus nigra) followed by infection with EV71 MP4. The bound EV71 was analyzed by ELISA and real-time
PCR, and the subsequent replication of EV71 in RD cells was detected by real-time PCR analysis. The binding of virus to RD cells treated with different
concentrations of MAA was reduced by 19% and 45% measured by ELISA (A) and by 37% and 68% measured by real-time PCR (C). The replication of
EV71 dropped 38% and 59% after MAA treatment measured by real-time PCR after 24 hours incubation (E). The virus binding of SNA treated cells
reduced by 18% and 38% measured by ELISA (B), and by 28% and 45% measured by real-time PCR (D). The replication of EV71 dropped 30% and 58%
after SNA treatment measured by RT-PCR after 24 hours incubation (F). **: P<0.01; ***: P<0.001 (two-tailed test). Each of the results was averaged
from at least six independent assays.
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http://www.biomedcentral.com/1471-2180/12/162hepatitis A virus [28]. Then, fetuin/asialofetuin blocking
assay was performed and the result indicated that sialylated
glycoproteins, such as fetuin, lactoferrin and milk proteins,
were inhibitors of EV71 infection [24,25,29]. In order to fur-
ther identify the carbohydrate epitopes for EV71 infection,
viral particles and recombinant viral capsid protein were
subjected to carbohydrate solution microarray analysis. But,we could not observe any positive binding signal for viral
particles or recombinant VP1 protein. It might be because
we don’t have sufficient sialylated epitopes in our microarray
library. Further investigations are in progress (collaborate
with CFG).
To further characterize the role of sialylation on EV71
cellular receptor, we isolated cell membrane sialylated
Figure 5 The infection and replication of EV71 to RD cells are affected by lectin treatment investigated with EV71-GFP infection. Cells
preincubated with or without MAA/SNA were infected with or without EV71-GFP. The cell number, CPE, and fluorescence intensity were
observed by fluorescence microscope. After 48 hours, higher fluorescence intensity was found in untreated cells than neuraminidase
pretreated cells.
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was a common and useful tool for proteomic and glyco-
mic analysis [41–45]. For instance, Butterfield et al.
enriched and analyzed abnormal glycoproteins from
brain of Alzheimer disease patient by using LAC [41].
Alvarez-Manilla and colleagues also identified potential
glycobiomarkers from embryonic stem cells with LAC
technology [43]. Hence, sialylated membrane proteins
were purified with MAA/SNA lectin-agarose column
from RD cell membrane extractions. Then, the purified
glycoproteins were treated with neuraminidase to re-
move the effect of sialic acid. The desialylated glycopro-
teins were subjected to immunoprecipitation assay that
pulled down proteins specifically interacted with EV71.
Not surprisingly, SCARB2 was observed in western blot-
ting of LAC purified fraction, neuraminidase treated
fraction, as well as the EV71 immunoprecipitated frac-
tion. It should be noted that the position of band in lane
4 (EV71 immunoprecipitated fraction) was inconsistent
with band in lane 3. This result may come from sample
preparation under non-reducing condition which could
not break SCARB2-viral protein interactions. These
observations prompted us to investigate the binding ofEV71 to sialylated and desialylated SCARB2. By using
VOPBA, we found that recombinant hSCARB2 lost some
of the binding ability to EV71 after desialylation. The
same phenomenon have been observed by Yamayoshi et
al who found that the interaction of EV71 with recom-
binant hSCARB2 was moderately decreased after remov-
ing N-glycans from hSCARB2 by enzymatic hydrolysis
[46]. Taken together, all of the results indicated that the
attachment of EV71 to cell surface receptor should be
assisted with sialic acids.
Conclusions
Based on our findings, we concluded that cell surface
sialylation was important for EV71 infection to RD and
SK-N-SH cells. Although the glycan epitopes for EV71
was still unclear, these evidences sufficiently supported
that sialylation of cell surface glycoproteins could assist
the attachment of EV71 to host cells. In addition, we
also demonstrated that SCARB2 was a sialylated glyco-
protein. Interactions between SCARB2 with EV71 were
decreased after desialylation. Our findings not only
demonstrated the important role of sialic acid in EV71
infection to RD and SK-N-SH cells, but also opened a
Figure 6 (See legend on next page.)
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Figure 6 The attachment and infection of EV71 4643 to SK-N-SH cells are affected by neuraminidase or sialic acid specific lectin
treatment. SK-N-SH cells were pretreated with neuraminidase, MAA or SNA before infected with EV71 4643. (A) The copy number of
EV71 dropped 44% and 59% in neuraminidase treated cells. (B) The copy number of EV71 reduced by 42% and 59% in MAA treated cells. (C) The
copy number of EV71 decreased by 31% and 52% in SNA treated cells. **: P< 0.01; ***: P< 0.001 (two-tailed test). Each of the results was averaged
from at least six independent assays.
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identification and characterization of glycans or proteins
which interact with EV71 are now in progress.Methods
Virus amplification and purification
RD and SK-N-SH cells (ATCC, Manassas, VA) were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) contained 10% fetal bovine serum (FBS),
2.0 mM L-glutamine, 100 IU of penicillin, and 100 μg of
streptomycin. The infectious clone of mouse-adapted
EV71 MP4, 4643 and EV71-GFP were obtained from
Dr. Jen-Ren Wang. GFP was located in the replicon
between P2 and P3 nonstructural regions. In vitro
transcription of the linear plasmid of MP4, 4643 and
EV71-GFP were performed by kit (Promega) and puri-
fied mRNA was transfected to RD cells (for MP4 and
EV71-GFP) or SK-N-SH (for 4643). Virus was amplified
in RD cells or SK-N-SH and cultivated using DMEM
with 2% FBS at 37°C for 16 to 24 hours. To prepare
virus stocks, viruses will be propagated for one moreFigure 7 Fetuin blocks the attachment of EV71 to RD cells.
Cells were preincubated with fetuin or asialofetuin and
infected with EV71. Asialofetuin showed no effect on virus binding,
but the attachment of EV71 to RD cells decreased by 12% to 14% in
fetuin preincubated cells. *: P< 0.05; **: P< 0.01 (two-tailed test).
Each of the results was averaged from at least seven independent
assays.passage in cells. Working stocks contain 108 PFU per
ml. The culture medium and cells were collected for
purification when CPE was observed. All of the viruses
were precipitated with poly ethylene glycol (PEG) and
purified by sucrose gradient ultracentrifugation.Preparation of EV71 specific monoclonal antibody (1 G3)
The hybridoma cells which produced monoclonal anti-
body (1 G3) against EV71 VP1 protein region was a gift
from Dr. Chun-Keung Yu. The hybridoma cells (106)
were injected intraperitoneally into 10-weeks old BALB/c
mice after pristane injection. Ascites was collected and
the 1 G3 monoclonal antibody was purified by protein-A
affinity column on AKTA prime plus (GE Healthcare).
The titer of antibody was quantified by ELISA assay.General procedures for virus binding assay
ELISA
Cells were seeded in 96 microtiter plate and cultured
with DMEM containing 10% FBS at 37°C for 72 hours.
EV71 MP4 (M.O.I = 100) or EV71 GFP were added into
the treated or untreated cells and incubated at 4°C for
3 hours. The reactions were mixed gently every 30
minutes. After wash, the cells were fixed with 4% paraf-
ormaldehyde and incubated with anti-EV71 antibodyFigure 8 Western blotting of glycoprotein fractions with
anti-SCARB2 antibody. Lane 1: RD cell membrane extracts;
Lane 2: MAA/SNA lectin affinity chromatography purified sialylated
glycoproteins; Lane 3: desialylated glycoproteins; Lane 4: desialylated
glycoproteins immunoprecipitated with EV71 MP4. All of the purified
proteins were subjected to western blotting and stained by anti-SCARB2
antibody. SCARB2 could be observed in all of the fractions. Band in lane
3 was slightly shifted down after neuraminidase treatment. But, owing
to non-reducing condition, band in lane 4 was slightly shifted up
compared to band in lane 3.
Figure 9 Interactions between recombinant hSCARB2 with
EV71 are reduced after desialylation. The binding is detected by
Viral-Overlaying Protein Binding Assay (VOPBA) with anti-EV71
antibody and HRP conjugated anti-mouse antibody on LAS-3000.
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phatase conjugated anti-mouse IgG (Sigma) was added
and incubated at room temperature for 2 hours. After
wash, substrate (p-nitrophenyl phosphate) solution was
added and incubated at room temperature for 30 min-
utes. The reactions were quenched by adding NaOH
(3.0 N) and measured the absorbance at 405 nm by
EnVisonTM 2103 Multilabel reader (PerkinElmer).
Flow cytometry
Treated and untreated cells (4 × 105/assay) harvested
from culture plate were washed with PBS once and incu-
bated with EV71 MP4 (M.O.I = 100) at 4°C for 3 hours.
After wash, the cells were fixed with 4% paraformalde-
hyde and incubated with anti-EV71 antibody 1 G3 at
room temperature for 2 hours. Alexa 488 conjugated
anti-mouse IgG (Invitrogen) was added into the reaction
and incubated at 4°C for 1 hour. The histograms of
bound viruses were analyzed by FACSCalibur flow cyt-
ometer (BD Biosciences).
Real-time PCR
Cells were seeded in 6 well plate (2.5 × 105/ well) and
cultured with DMEM containing 10% FBS at 37°C for 72
hours. Treated and untreated cells were incubated with
EV71 MP4 or 4643 (M.O.I = 10) at 4°C for 1 hour. The
total RNA was extracted by RNeasy protect bacteria
mini kit (QIAGEN) and the copy number of viral RNA
was measured by using LightCycler RNA Master HybP-
robe kit (Roche). The copy number of viral RNA was
calculated using a standard curve. The replication of
EV71 was also measured by real-time PCR. Treated anduntreated cells were incubated with EV71 MP4 or 4643
(M.O.I = 1) at 4°C for 1 hour. After the unbounded virus
was removed, culture medium was added into the well
and incubated at 37°C for 24 hours. The total RNA was
measured as described above.
EV71-GFP infection assay
RD cells were seeded in 96 well plate (1 × 104/ well) and
cultured with DMEM containing 10 % FBS at 37°C for
72 hours. Treated and untreated cells were incubated
with EV71-GFP (M.O.I = 15) at 37°C for 1 hour. After
the unbounded virus was removed, culture medium was
added was added into the well and incubated at 37°C for
48 hours. The cell number, CPE, and fluorescence inten-
sity were observed by fluorescence microscope at 0, 24
and 48 hours.
General procedures for inhibition assays
All of the inhibition assays were performed by treating
cells with inhibitors, enzyme, or lectins before EV71 in-
fection. Virus was incubated with cells at 4°C for 3 hours
in binding assay, and worked at 37°C for 3 hours in
virus infection assay. The bound EV71 was analyzed by
ELISA, flow cytometry and real-time PCR followed the
procedures mentioned above. The copy number of EV71
was detected by real-time PCR analysis.
Inhibitor treatment
Cells were incubated with 0.5 mg/ml tunicamycin
(Sigma) or 3.0 mM benzyl-α-GalNAc (Toronto Research
Chemicals Inc.) at 37°C for 24 or 48 hours, respectively.
After wash, the cells were subjected to virus infection.
Neuraminidase treatment
Cells were incubated with 0.5 to 25 mU of neuraminid-
ase (Roche, 11080752001) with 4 mM CaCl2 in serum-
free DMEM at 37°C for 3 hours followed by wash and
EV71 infection. For detecting cell surface SCARB2, the
neuraminidase treated cells (10 mU) were incubated
with mouse anti-SCARB2 antibody (1:100) and FITC-
conjugated goat anti-mouse antibody (1:500) at 4°C for
30 minutes. After wash for three times, the cells were
analyzed by FACS caliber with Cell Quest Pro software
(BD Biosciences).
Lectin competition
Cells were incubated with 2 to 125 μg/ml of MAA
(maackia amurensis) or SNA (sambucus nigra) at 4°C
for 30 minutes. After wash, the cells were subjected to
virus infection.
Fetuin and asialofetuin treatment
RD cells (2x104) were incubated with 2/25 μg/ml of
fetuin or asialofetuin at 4°C for 30 minute followed by
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ing of EV71 was measured by ELISA assay.
Isolation of cell membrane glycoproteins and sialylated
proteins
RD cells were harvested and homogenized in ice-cold
homogenization buffer (20 mM Tris–HCl, pH 7.5,
2.0 mM EDTA, 1.0 mM DTT and protein inhibitor cock-
tail) by using sonicator (Chrom Tech). Cell lysates were
obtained by centrifugation and cell pellet was resolved
in homogenization buffer. The collected membrane
fractions from centrifugation were resuspended in
homogenization buffer and analyzed by western blotting.
Then, membrane protein fractions were subjected to lec-
tin affinity chromatography that was packaged with SNA
and MAA agarose beads (EY Laboratories). The sialy-
lated glycoproteins were eluted by 20 mM ethylenedi-
amine and all of the fractions were collected for further
characterization and analyzed by western blotting with
anti-SCARB2 monoclonal antibody.
Immunoprecipitation assay
The purified sialylated glycoproteins were incubated
with 5 units of neuraminidase at 4°C for 16 hours. The
reaction mixture was transferred to an eppendorf which
contained EV71 viral particles, anti-EV71 antibody, and
protein G agarose beads. The reaction was incubated at
37°C for 12 hours and the bound proteins were pulled
down by centrifugation. After unbound proteins were
removed, the agarose beads were washed with PBS buf-
fer for three times and added glycin-HCl (pH 2.0) to
break the bindings. The reaction solution was centri-
fuged to remove Protein A agarose beads and the bound
glycoproteins were concentrated and analyzed by west-
ern blotting with anti-SCARB2 monoclonal antibody.
Interactions of EV71 to recombinant hSCARB2 - Viral-
Overlaying Protein Binding Assay (VOPBA)
Recombinant h-SCARB-2 protein was purchased from
Abscience (11063-H03H). 25 μg of the h-SCARB-2 pro-
teins were pretreated with or without neuraminidase
(10 mU, Roche, 11080752001) at 37°C. After 17 hours,
the proteins were subjected to 10% polyacrylamide gel
electrophoresis under non-reducing conditions and
transferred to nitrocellulose membrane which was block
with binding buffer (1% BSA, 154 mM NaCl, 0.05%
Tween-20, 1 mM CaCl2) at 4°C for 16 hours. The mem-
brane was incubated with EV71 in binding buffer at 4°C
for 16 hours with gentle rocking. After washed three
times with binding buffer, the membrane was incubated
with anti-virus antibody (1:2000, Millipore, Mab979) at
room temperature for 2 hours. HRP conjugated goat
anti-mouse IgG antibody (1:5000) was then added, incu-
bated at room temperature for 1 hour and washed bybinding buffer for three times. The images were cap-
tured by Fujifilm LAS-3000.
Western blotting
15 μg of h-SCARB-2 proteins were pretreated with or
without neuraminidase (10 mU, Roche, 11080752001) at
37°C. After 17 hours, the proteins were denatured in
95°C for 10 min and subjected to 10% polyacrylamide
gel electrophoresis. Then, the proteins were transferred
to nitrocellulose membrane and blocked with 5% milk
with PBS-T at room temperature for 1 hour. The
membrane was incubated with anti-SCARB-2 antibody
(Abcam, ab106519) at 4°C for 16 h with gentle rocking,
and incubated with HRP-conjugated goat anti-mouse
IgG antibody at room temperature for 1 hour. The
images were analyzed by Fujifilm LAS-3000.
Statistical analysis
Statistical analysis was performed using student’s T-test
for determination of statistical significance. The value of
P< 0.05 was considered to indicate statistical signifi-
cance. (*: P < 0.05; **: P < 0.01; ***: P < 0.001).
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